Fol. Biol. 2006, 52, 137-148
https://doi.org/10.14712/fb2006052040137
Protein Kinase Inhibitors
References
1. , T., Yoshida, T., Tsujita, T., Shimizu, M., Mizukami, T., Okabe, M., Akinaga, S. (1997) G1 phase accumulation induced by UCN-01 is associated with phosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res. 57, 1495-1501.
2. , C. (2003) Targeting HER1/EGFR: a molecular approach to cancer therapy. Sem. Oncol. 30 (Suppl. 7), 3–14.
<https://doi.org/10.1016/S0093-7754(03)70010-4>
3. , F., Tchouhadjian, C., Doddoli, C., Villani, P., Greillier, G., Kleisbauer, J. P., Thomas, P., Astoul, P. (2005) Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective. Fundam. Clin. Pharmacol. 19, 385-393.
<https://doi.org/10.1111/j.1472-8206.2005.00323.x>
4. , R. K., Boehm, I., Attwood, P. V., Watt, P. M., Bogoyevitch M. A. (2004) The critical features and the mechanism of inhibition of a kinase interaction motif-based peptide inhibitor of JNK. J. Biol. Chem. 279, 36327–36338.
<https://doi.org/10.1074/jbc.M402181200>
5. , F., Erwin-Cohen, R. A., Wang, M. E., Trawick, B. W., Qu, X., Verani, R., Kahan, B. D., Stepkowski, S. M., Kirken, R. A. (2001) Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts. J. Immunol. 166, 3724–3732.
<https://doi.org/10.4049/jimmunol.166.6.3724>
6. , S., de Bono, J. (2005) Drugging cell cycle kinases in cancer therapy. Curr. Drug Targets 6, 325-335.
<https://doi.org/10.2174/1389450053765824>
7. , M. A., Barr, R. K., Ketterman, A. J. (2005) Peptide inhibitors of protein kinases – discovery, characterisation and use. Biochim. Biophys. Acta 1754, 79-99.
<https://doi.org/10.1016/j.bbapap.2005.07.025>
8. , F. D., Karagyozov, L., Uecker, A., Serve, H., Botzki, A., Mahboobi, S., Dove, S. (2003) A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571. J. Biol. Chem. 278, 5148-5155.
<https://doi.org/10.1074/jbc.M209861200>
9. , C., Oberson, A., Negri, S., Sauser, C., Schorderet, D. F. (2001) Cell-permeable peptide inhibitors of JNK: novel blockers of β-cell death. Diabetes 50, 77–82.
<https://doi.org/10.2337/diabetes.50.1.77>
10. , C., Terme, M., Taieb, J., Menard, C., Flament, C., Robert, C., Maruyama, K., Wakasugi, H., Angevin, E., Thielemans, K., Le Cesne, A., Chung-Scott, V., Lazar, V., Tchou, I., Crepineau, F., Lemoine, F., Bernard, J., Fletcher, J. A., Turhan, A., Blay, J. Y., Spatz, A., Emile, J. F., Heinrich, M. C., Mecheri, S., Tursz, T., Zitvogel, L. (2004) Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J. Clin. Invest. 114, 379-388.
<https://doi.org/10.1172/JCI21102>
11. , D. C., O’Shea, J. J., Changelian, P. S. (2004) JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants. Trends Mol. Med. 10, 532-541.
<https://doi.org/10.1016/j.molmed.2004.09.007>
12. , C., Gassel, M., Hidaka, H., Kinzel, V., Huber, R., Engh, R. A., Bossemeyer, D. (2003) Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity. Structure 11, 1595-1607.
<https://doi.org/10.1016/j.str.2003.11.002>
13. , J. R., Koretke, K. K., Birkeland, M. L., Sanseau, P., Patrick, D. R. (2004) Evolutionary relationships of Aurora kinases: implications for model organism studies and the development of anti-cancer drugs. BMC Evol. Biol. 4, 39.
<https://doi.org/10.1186/1471-2148-4-39>
14. , C., Nagel-Wolfrum, K., Kunz, C., Wittig, I., Butz, K., Hoppe-Seyler, F., Groner B. (2003) Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells. J. Biol. Chem. 278, 37610–37621.
<https://doi.org/10.1074/jbc.M301629200>
15. , E., Cioffi, C. L., Law, N., Stover, D., OhnoJones, S., Drucker, B. J., Lydon, N. B. (2000) Abl proteintyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295, 139-145.
16. , T. R. Jr., Yao, Z. J., Liu, D. G., Voigt, J., Gao Y. (2001) Phosphoryltyrosyl mimetics in the design of peptide-based signal transduction inhibitors. Biopolymers 60, 32–44.
<https://doi.org/10.1002/1097-0282(2001)60:1<32::AID-BIP1002>3.0.CO;2-I>
17. , B., Lahusen, T., Singh, S., Loaiza-Perez, A., Worland, P. J., Pestell, R., Albanese, C., Sausville, E. A., Senderowicz, A. M. (1999) Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res. 59, 4634-4641.
18. , L., Jones, Y., Ellisman, M. H., Goldstein, L. S., Karin, M. (2003) JNK1 is required for maintenance of neuronal microtubules and controls phosphorylation of microtubule-associated proteins. Dev. Cell 4, 521–533.
<https://doi.org/10.1016/S1534-5807(03)00094-7>
19. , P. S., Flanagan, M. E., Ball, D. J., Kent, C. R., Magnuson, K. S., Martin, W. H., Rizzuti, B. J., Sawyer, P. S., Perry, B. D., Brissette, W. H., McCurdy, S. P., Kudlacz, E. M., Conklyn, M. J., Elliott, E. A., Koslov, E. R., Fisher, M. B., Strelevitz, T. J., Yoon, K., Whipple, D. A., Sun, J., Munchhof, M. J., Doty, J. L., Casavant, J. M., Blumenkopf, T. A., Hines, M., Brown, M. F., Lillie, B. M., Subramanyam, C., Shang-Poa, C., Milici, A. J., Beckius, G. E., Moyer, J. D., Su, C., Woodworth, T. G., Gaweco, A. S., Beals, C. R., Littman, B. H., Fisher, D. A., Smith, J. F., Zagouras, P., Magna, H. A., Saltarelli, M. J., Johnson, K. S., Nelms, L. F., Des Etages, S. G., Hayes, L. S., Kawabata, T. T., Finco-Kent, D., Baker, D. L., Larson, M., Si, M. S., Paniagua, R., Higgins, J., Holm, B., Reitz, B., Zhou, Y. J., Morris, R. E., O’Shea, J. J., Borie, D. C. (2003) Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302, 875–878.
<https://doi.org/10.1126/science.1087061>
20. , G. M. (2004) Novel protein kinases and molecular mechanisms of autoinhibition. Curr. Opin. Struct. Biol. 14, 700-705.
<https://doi.org/10.1016/j.sbi.2004.10.011>
21. , E. T., Smiciene, G., Hongisto, V., Cao, J., Brecht, S., Herdegen, T., Courtney, M. J. (2002) c-Jun N-terminal protein kinase (JNK) 2/3 is specifically activated by stress, mediating c-Jun activation, in the presence of constitutive JNK1 activity in cerebellar neurons. J. Neurosci. 22, 4335–4345.
<https://doi.org/10.1523/JNEUROSCI.22-11-04335.2002>
22. , J., Kantarjian, H. (2005) New targeted approaches in chronic myeloid leukemia. J. Clin. Oncol. 23, 6316-6324.
<https://doi.org/10.1200/JCO.2005.05.009>
23. , G. Q., Baltimore, D. (1992) Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc. Natl. Acad. Sci. USA 85, 9312-9316.
<https://doi.org/10.1073/pnas.85.23.9312>
24. , M. W. (2004) Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia. J. Cancer Res. Clin. Oncol. 130, 59-72.
<https://doi.org/10.1007/s00432-003-0502-2>
25. , M. W., Goldman, J. M., Melo, J. V. (2000) The molecular biology of chronic myeloid leukemia. Blood 96, 3343-3356.
<https://doi.org/10.1182/blood.V96.10.3343>
26. , A. L., Cambareri, A. C., Zannettino, A. C., Miller, B. L., Roberty, K. V., Hughes, T. P., Lyons, A. B. (2005) Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 105, 3127-3132.
<https://doi.org/10.1182/blood-2004-10-3967>
27. , M. R. (2004) Early phase I data on an irreversible panerb inhibitor: CI-1033. What did we learn? J. Chemother. 16 (Suppl 4), 44-48.
<https://doi.org/10.1179/joc.2004.16.Supplement-1.44>
28. , C., Keen, N., Taylor, S. S. (2004) The Ipl1/Aurora kinase family: methods of inhibition and functional analysis in mammalian cells. Methods Mol. Biol. 296, 371-382.
29. , A., Medeiros, F., McConarty, B., Joseph, N. E., Panigrahy, D., Singer, S., Fletcher, C. D., Demetri, G. D., Fletcher, J. A. (2004a) Mechanisms of oncogenic KIT sigVol. 52 nal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 23, 3999-4006.
<https://doi.org/10.1038/sj.onc.1207525>
30. , A., Joseph, N. E., Medeiros, F., Smith, F., Hornick, J. L., Heinrich, M. C., Corless, C. L., Demetri, G. D., Fletcher, C. D., Fletcher, J. A. (2004b) Protein kinase C θ (PKCθ) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res. 64, 5127-5131.
<https://doi.org/10.1158/0008-5472.CAN-04-0559>
31. , F., Yuan, J., Strebhardt, K. (2005) Polo-like kinases and oncogenesis. Oncogene 24, 267-276.
<https://doi.org/10.1038/sj.onc.1208273>
32. , R. T., Xu, X., Williams, J. W., Gong, H., Finnegan, A., Chong, A. S. (1997) The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J. Immunol. 159, 22-27.
<https://doi.org/10.4049/jimmunol.159.1.22>
33. , J. H., Leung, J., Bruner, R. J., Caligiuri, M. A., Briesewitz, R. (2003) Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc. Natl. Acad. Sci. USA 100, 7830-7835.
<https://doi.org/10.1073/pnas.0932698100>
34. , K., Baker, S. J., Cosenza, S. C., John, P., Kang, A. D., Robell, K. A., Reddy, M. V., Reddy, E. P. (2005) A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc. Natl. Acad. Sci. USA 102, 1992-1997.
<https://doi.org/10.1073/pnas.0408283102>
35. , E. A., Bebbington, D., Moore, J., Rasmussen, R. K., Ajose-Adeogun, A. O., Nakayama, T., Graham, J. A., Demur, C., Hercend, T., Diu-Hercend, A., Su, M., Golec, J. M., Miller, K. M. (2004) VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. 10, 262-267.
<https://doi.org/10.1038/nm1003>
36. , S., Cole, R. W., LaTerra, S., Zimmer, C., Schnapp, G., Walter, R., Heckel, A., van Meel, J., Rieder, C. L., Peters J. M. (2003) The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J. Cell Biol. 161, 281-294.
<https://doi.org/10.1083/jcb.200208092>
37. , T. L. (2001) Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory. Br. J. Haematol. 113, 11-23.
<https://doi.org/10.1046/j.1365-2141.2001.02558.x>
38. , J. R., Liu, R., Enstrom, A. M., Lou, Q., Lam, K. S. (2003) Development and characterization of potent and specific peptide inhibitors of p60c-src protein tyrosine kinase using pseudosubstrate-based inhibitor design approach. J. Pept. Res. 62, 260-268.
<https://doi.org/10.1046/j.1399-3011.2003.00094.x>
39. , N., Taylor, S. (2004) Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer 4, 927-936.
<https://doi.org/10.1038/nrc1502>
40. , S., Ramakrishna, N., Sauvageot, C., Stiles, C. D., Wen, P. Y. (2005) Targeted molecular therapy of malignant gliomas. Curr. Neurol. Neurosci. Rep. 5, 186-197.
<https://doi.org/10.1007/s11910-005-0046-8>
41. , T., Alberta, J. A., Zdunek, P. R., Acar, M., Iannarelli, P., O’Reilly, T., Buchdunger. E, Black, P. M., Stiles, C. D. (2000) Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 60, 5143–5150.
42. , R. A., Erwin, R. A., Taub, D., Murphy, W. J., Behbod, F., Wang, L., Pericle, F., Farrar, W. L. (1999) Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells. J. Leukoc. Biol. 65, 891-899.
<https://doi.org/10.1002/jlb.65.6.891>
43. , Z. A., Shokat, K. M. (2005) Features of selective kinase inhibitors. Chem. Biol. 12, 621-637.
<https://doi.org/10.1016/j.chembiol.2005.04.011>
44. , D., Kular, G. S., Schuttelkopf, A. W., Deak, M., Prakash, K. R., Bain, J., Elliott, M., Garrido-Franco, M., Kozikowski, A. P., Alessi, D. R., van Aalten, D. M. (2004) Interactions of LY333531 and other bisindolyl maleimide inhibitors with PDK1. Structure 12, 215-226.
<https://doi.org/10.1016/j.str.2004.01.005>
45. , L., Soltani, K., Lacouture, M. E. (2005) The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies. J. Am. Acad. Dermatol. 53, 291-302.
<https://doi.org/10.1016/j.jaad.2005.02.011>
46. , R., Passamonti, F., Buser, A. S., Teo, S. S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., Skoda, R. C. (2005) A gain of function mutations of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790.
<https://doi.org/10.1056/NEJMoa051113>
47. , D. S., Van Etten, R. A. (2005) Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353, 172-187.
<https://doi.org/10.1056/NEJMra044389>
48. , G. W., Honsawek, S., Litz, J., Buchdunger, E. (2000) The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin. Cancer. Res. 6, 3319-3326.
49. , E. L., Sordella, R., Bell, D. W. (2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. USA 102, 7665-7670.
<https://doi.org/10.1073/pnas.0502860102>
50. , P., Corbin, A. S., Stoffregen, E. P., Deininger, M. W., Druker, B. J. (2002) Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res. 62, 7149-7153.
51. , D. J., Burke, D. J. (2003) The spindle assembly and spindle position checkpoints. Annu. Rev. Genet. 37, 251-282.
<https://doi.org/10.1146/annurev.genet.37.042203.120656>
52. , L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A., Das, J., Doweyko, A. M., Fairchild, C., Hunt, J. T., Inigo, I., Johnston, K., Kamath, A., Kan, D., Klei, H., Marathe, P., Pang, S., Peterson, R., Pitt, S., Schieven, G. L., Schmidt, R. J., Tokarski, J., Wen, M. L., Wityak, J., Borzilleri, R. M. (2004) Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658-6661.
<https://doi.org/10.1021/jm049486a>
53. , N. B., Druker, B. J. (2004) Lessons learned from the development of imatinib. Leuk. Res. 28, S29-38.
<https://doi.org/10.1016/j.leukres.2003.10.002>
54. , A. C., Glicksman, M. A., Basma, A. N., Walton, K. M., Knight, E. Jr., Murphy, C. A., Bartlett, B. A., Finn, J. P., Angeles, T., Matsuda, Y., Neff, N. T., Dionne, C. A. (1998) Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway. J. Neurosci. 18, 104-111.
<https://doi.org/10.1523/JNEUROSCI.18-01-00104.1998>
55. , S. J., Blake, D., Clarke, R., Cowan, A., Cummings, L., Fischer, P. M., MacKenzie, M., Melville, J., Stewart, K., Wang, S., Zhelev, N., Zheleva, D., Lane, D. P. (2002) In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer 102, 463-468.
<https://doi.org/10.1002/ijc.10738>
56. , C., Mezna, M., Fischer, P. M. (2005) Progress in the discovery of polo-like kinase inhibitors. Curr. Top. Med. Chem. 5, 181-197.
<https://doi.org/10.2174/1568026053507660>
57. , J. (2000) Blockade of receptors for growth factors: an anticancer therapy – the fourth annual Joseph H. Burchenal American Association of Cancer Research Clinical Research Award lecture. Clin. Cancer Res. 6, 747-753.
58. , F. J., Espino, P. S., Cann, K. L., Bristow, N., McCrea, K., Los, M. (2005) Anti-tumor chemotherapy utilizing peptide-based approaches – apoptotic pathways, kinases, and proteasome as targets. Arch. Immunol. Ther. Exp. (Warsz). 53, 47-60.
59. , N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leeder, J. S., Freedman, M., Cohen, A., Gazit, A., Levitzki, A., Roifman, C. M. (1996) Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379, 645-648.
<https://doi.org/10.1038/379645a0>
60. , R. N., Xiao, H. Y., Kim, K. S., Lu, S., Han, W. C., Barbosa, S. A., Hunt, J. T., Rawlins, D. B., Shan, W., Ahmed, S. Z., Qian, L., Chen, B. C., Zhao, R., Bednarz, M. S., Kellar, K. A., Mulheron, J. G., Batorsky, R., Roongta, U., Kamath, A., Marathe, P., Ranadive, S. A., Sack, J. S., Tokarski, J. S., Pavletich, N. P., Lee, F. Y., Webster, K. R., Kimball, S. D. (2004) N-(cycloalkylamino)acyl-2aminothiazole inhibitors of cyclin-dependent kinase 2. N[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J. Med. Chem. 47, 1719-1728.
<https://doi.org/10.1021/jm0305568>
61. , M., McMahon, G., Sun, L., Tang, C., Hirth, P., Yeh, B. K., Hubbard, S. R., Schlessinger, J. (1997) Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276, 955-960.
<https://doi.org/10.1126/science.276.5314.955>
62. , C. D., Lim, K. B., Sridhar, V., Zou, H., Chien, E. Y., Sang, B. C., Nowakowski, J., Kassel, D. B., Cronin, C. N., McRee, D. E. (2003) Structure of a c-kit product complex reveals the basis for kinase transactivation. J. Biol. Chem. 278, 31461-31464.
<https://doi.org/10.1074/jbc.C300186200>
63. , C. D., Fabbro, D., Hosfield, D. J. (2004) Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors. Curr. Opin. Drug. Discov. Devel. 7, 639-648.
64. , B. K., Mack, H., Teusch, N. (2005) Rho kinase, a promising drug target for neurological disorders. Nat. Rev. Drug. Discov. 4, 387-398.
<https://doi.org/10.1038/nrd1719>
65. , H., Kobayashi, M., Jin, T., Taguchi, T., Sugimoto, T., Nakano, T., Hamada, S., Araki, K. (2005) STI571 (Glivec) inhibits the interaction between c-kit and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST-T1. Cancer Sci. 96, 116-119.
<https://doi.org/10.1111/j.1349-7006.2005.00018.x>
66. , W. J., Dou, F., Cai, D., Veach, D., Jean, S., Li, Y., Bornmann, W. J., Clarkson, B., Xu, H., Greengard, P. (2003) Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc. Natl. Acad. Sci. USA 100, 12444-12449.
<https://doi.org/10.1073/pnas.1534745100>
67. , T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W., Druker, B. J. (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 65, 4500-4505.
<https://doi.org/10.1158/0008-5472.CAN-05-0259>
68. , Y., Sugi, N. H., Nagasu, T., Owa, T., Watanabe, T., Koyanagi, N., Yoshino, H., Kitoh, K., Yoshimatsu, K. (2001) E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur. J. Cancer 37, 2275-2282.
<https://doi.org/10.1016/S0959-8049(01)00275-1>
69. Study Group (2004) The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD. Neurology 62, 330-332.
<https://doi.org/10.1212/01.WNL.0000103882.56507.20>
70. , S. C., Shukla, G. S., Armstrong, A. L., Peterson, D., Fuller, S. P., Godin, K., Kingsley-Richards, S. L., Weaver, D. L., Bond, J., Krag, D. N. (2004) Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells. Int. J. Cancer 111, 951-960.
<https://doi.org/10.1002/ijc.20306>
71. , J. J. (2005) HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J. Neurooncol. 74, 77-86.
<https://doi.org/10.1007/s11060-005-0603-7>
72. , R., Giri, S., Singh, A. K., Singh, I. (2006) Rho/ROCK pathway as a target of tumor therapy. J. Neurosci. Res. 83, 243-255.
<https://doi.org/10.1002/jnr.20707>
73. , J., Pargellis, C. A., Cirillo, P. F., Gilmore, T., Hickey, E. R., Peet, G. W., Proto, A., Swinamer, A., Moss, N. (2003) The kinetics of binding to p38MAP kinase by analogues of BIRB 796. Bioorg. Med. Chem. 13, 3101-3104.
<https://doi.org/10.1016/S0960-894X(03)00656-5>
74. , P., Alitalo, K. (2003) Double target for tumor mass destruction. J. Clin. Invest. 111, 1277-1280.
<https://doi.org/10.1172/JCI200318539>
75. , M., Salgia, R. (2004) Targeting c-kit mutations: basic science to novel therapies. Leuk. Res. 28, S11-20.
<https://doi.org/10.1016/j.leukres.2003.10.004>
76. , D. G., Antman, K. H. (2002) Imatinib mesylate – a new oral targeted therapy. N. Engl. J. Med. 346, 683-693.
<https://doi.org/10.1056/NEJMra013339>
77. , L. M. (2002) Cyclin-dependent kinases as cellular targets for antiviral drugs. J Antimicrob. Chemother. 50, 779-792.
<https://doi.org/10.1093/jac/dkf227>
78. , L. M. (2005) Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs. Curr. Drug Targets Infect. Disord. 5, 29-37.
<https://doi.org/10.2174/1568005053174609>
79. , L. M., Rosenberg, A., Schaffer, P.A. (2000) Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins. J. Virol. 74, 2107-2120.
<https://doi.org/10.1128/JVI.74.5.2107-2120.2000>
80. , A. M., Sausville, E. A. (2005) Preclinical and clinical development of cyclin-dependent kinase modulators. J. Nat. Cancer Inst. 92, 376-387.
<https://doi.org/10.1093/jnci/92.5.376>
81. , I., Šefc, L., Nečas, E. (2006) Protein kinases, their functions and implication in cancer and other diseases. Folia Biol. (Praha) 52, 81-101.
82. , R. T. (2005) Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate. Curr. Hematol. Rep. 4, 235-237.
83. , A., Johnson, V. L., Albertella, M., Taylor, S. S. (2001) Aneuploid colon cancer cells have a robust spindle checkpoint. EMBO Rep. 2, 609-614.
<https://doi.org/10.1093/embo-reports/kve127>
84. , L., Pav, S., White, D. M., Rogers, S., Crane, K. M., Cywin, C. L., Brown, M. L., Pargellis, C. A. (1997) A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat. Struct. Biol. 4, 311-316.
<https://doi.org/10.1038/nsb0497-311>
85. , P., Bold, G., Buchdunger, E., Caravatti, G., Furet, P., Manley, P., O’Reilly, T., Wood, J., Zimmermann, J. (2001) Tyrosine kinase inhibitors: from rational design to clinical trials. Med. Res. Rev. 21, 499-512.
<https://doi.org/10.1002/med.1022>
86. , D., Lenz, H. J. (2005) Epidermal growth factor receptor as a target for chemotherapy. Clin. Colorectal Cancer 5, S19-27.
<https://doi.org/10.3816/CCC.2005.s.003>
87. , J. (2004) KIT and PDGF as targets. Cancer Treat. Res. 120, 117-27.
<https://doi.org/10.1007/1-4020-7856-0_7>
88. , J., Havlicek, L., Strnad, M., Blow, J. J., DonellaDeana, A., Pinna, L., Letham, D. S., Kato, J., Detivaud, L., Leclerc, S., Meijer, L. (1994) Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 224, 771-786.
<https://doi.org/10.1111/j.1432-1033.1994.00771.x>
89. , V., Herdegen, T. (2005) Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage. Trends Pharmacol. Sci. 26, 455-461.
90. , L. H., Besirli, C. G., Johnson, E. M. Jr. (2004) Mixedlineage kinases: a target for the prevention of neurodegeneration. Annu. Rev. Pharmacol. Toxicol. 44, 451-474.
<https://doi.org/10.1146/annurev.pharmtox.44.101802.121840>
91. , Q., Fan, S., Eastman, A., Worland, P. J., Sausville, E. A., O’Connor, P. M. (1996) UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst. 88, 956-965.
<https://doi.org/10.1093/jnci/88.14.956>
92. , E., Manley, P. W., Breitenstein, W., Bruggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., Kung, A. L., Mestan, J., Daley, G. Q., Callahan, L., Catley, L., Cavazza, C., Azam, M., Neuberg, D., Wright, R. D., Gilliland, D. G., Griffin, J. D. (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7, 129-141.
<https://doi.org/10.1016/j.ccr.2005.01.007>
93. , N. C., Richardson, J. A., Egorin, M., Ilaria, Jr. R. L. (2003) The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood 101, 5010-5013.
<https://doi.org/10.1182/blood-2002-10-3059>
94. , S., McLaughlin, J., Cheng, D., Zhang, C., Shokat, K. M., Witte, O. N. (2004) Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations. Proc. Natl. Acad. Sci. USA 101, 17456-17461.
<https://doi.org/10.1073/pnas.0407061101>
95. , J. M., Bold, G., Buchdunger, E., Cozens, R., Ferrari, S., Frei, J., Hofmann, F., Mestan, J., Mett, H., O’Reilly, T., Persohn, E., Rosel, J., Schnell, C. C., Stover, D., Theuer, A., Towbin, H., Wenger, F. W., Woods-Cook, K., Menrad, A., Siemeister, G., Schirner, M., Thierauch, K. H., Schneider, M. R., Drevs, J., Martiny-Baron, G., Totzke, F., Marme, D. (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 60, 2178-2189.
96. , P., Gao, W. Y., Turner, S., Ducatman, B. S. (2003) Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol. Cancer 2, 1.
<https://doi.org/10.1186/1476-4598-2-1>
97. , E., Bange, J., Ullrich, A. (2002) Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol. Med. 8, 17-23.
<https://doi.org/10.1016/S1471-4914(01)02217-1>
